Management of exercise-induced bronchospasm in children: Role of long-acting β2-adrenergic receptor agonists

Pediatric Asthma, Allergy and Immunology

Volumn 21, Issue 2, 2008, Pages 59-71

  Milgrom, Henry ^a   Dockhorn, Robert J ^b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b AirPharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FORMOTEROL; NEDOCROMIL SODIUM; SALBUTAMOL; SALMETEROL; TERBUTALINE;

ANGIONEUROTIC EDEMA; BRONCHOSPASM; CAREGIVER; CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; EXERCISE INDUCED ASTHMA; HEART PALPITATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPOKALEMIA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; SLEEP DISORDER; TACHYCARDIA; TREMOR; URTICARIA;

EID: 51849093097     PISSN: 08831874     EISSN: None     Source Type: Journal    
DOI: 10.1089/pai.2007.0023.59     Document Type: Review

References (85)

1. Anderson SD. Exercise-induced asthma in children: a marker of airway inflammation. Med J Aust 2002; 177 Suppl:S61-63.
2. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthupdt.htm. Last accessed August 29, 2007.
3. Milgrom H, Taussig LM. Keeping children with exercise-induced asthma active. Pediatrics 1999; 104:e38.
4. Hermansen CL, Kirchner JT. Identifying exercise-induced bronchospasm. Treatment hinges on distinguishing it from chronic asthma. Postgrad Med 2004; 115:15-16, 21-25.
5. Weiler JM, Bonini S, Coifman R, Craig T, Delgado L, Capao-Filipe M, Passali D, Randolph C, Storms W. American Academy of Allergy, Asthma & Immunology Work Group report: exercise-induced asthma. J Allergy Clin Immunol 2007; 119:1349-1358.
6. Zawadski DK, Lenner KA, McFadden ER, Jr. Re-examination of the late asthmatic response to exercise. Am Rev Respir Dis 1988; 137:837-841.
7. Sinha T, Dav id AK. Recognition and management of exercise-induced bronchospasm. Am Fam Physician 2003; 67:769-74, 675.
8. Landwehr LP, Wood RP, 2nd, Blager FB, Milgrom H. Vocal cord dysfunction mimicking exercise-induced bronchospasm in adolescents. Pediatrics 1996; 98:971-974.
9. Sheth KK. Activity-induced asthma. Pediatr Clin North Am 2003; 50:697-716.
10. Massie J. Exercise-induced asthma in children. Paediatr Drugs 2002; 4:267-278.
11. Tan RA, Spector SL. Exercise-induced asthma: diagnosis and management. Ann Allergy Asthma Immunol 2002; 89:226-235; quiz 35-7, 97.
12. Milgrom H, Exercise-induced asthma in the competitive athlete. In: Szefler S, ed. Childhood Asthma. New York, NY: Taylor & Francis Group, 2006.
13. Storms WW. Asthma associated with exercise. Immunol Allergy Clin North Am 2005; 25:31-43.
14. Bloom B, Dey AN, Freeman G. Summary health statistics for U.S. Children: National Health Interview Survey, 2005. Vital Health Stat 2006; 10:1-84.
15. Pierson WE, Voy RO. Exercise-induced bronchospasm in the XXIII summer Olympic games. N Engl Reg Allergy Proc 1988; 9:209-213.
16. Wilber RL, Rundell KW, Szmedra L, Jenkinson DM, Im J, Drake SD. Incidence of exercise-induced bronchospasm in Olympic winter sport athletes. Med Sci Sports Exerc 2000; 32: 732-737.
17. Anderson SD, Daviskas E. The mechanism of exercise-induced asthma is. J Allergy Clin Immunol 2000; 106:453-459.
18. Anderson SD, Kippelen P. Exercise-induced bronchoconstriction: pathogenesis. Curr Allergy Asthma Rep 2005; 5:116-122.
19. Anderson SD, Daviskas E. The airway microvasculature and exercise induced asthma. Thorax 1992; 47:748-752.
20. Deal EC, Jr., McFadden ER, Jr., Ingram RH, Jr., Strauss RH, Jaeger JJ. Role of respiratory heat exchange in production of exercise-induced asthma. J Appl Physiol 1979; 46:467-475.
21. McFadden ER, Jr., Lenner KA, Strohl KP. Postexertional airway rewarming and thermally induced asthma. New insights into pathophysiology and possible pathogenesis. J Clin Invest 1986; 78:18-25.
22. McFadden ER, Jr. Hypothesis: exercise-induced asthma as a vascular phenomenon. Lancet 1990; 335:880-883.
23. Capetandes A, Zhuang M, Haque FN, Xie L, Frieri M. Vascular endothelial growth factor is increased by human pulmonary cells stimulated with Dermatophagoides sp. extract. Allergy Asthma Proc 2007; 28:324-330.
24. Anderson SD. Is there a unifying hypothesis for exercise-induced asthma? J Allergy Clin Immunol 1984; 73:660-665.
25. Hermansen CL. Exercise-induced bronchospasm vs. exercise-induced asthma. Am Fam Physician 2004; 69:808; author reply, 10.
26. Godfrey S. Exercise-induced asthma-clinical, physiological, and therapeutic implications. J Allergy Clin Immunol 1975; 56:1-17.
27. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309-329.
28. Cooper DM, Radom-Aizik S, Schwindt C, Zaldivar F, Jr. Dangerous exercise: lessons learned from dysregulated inflammatory responses to physical activity. J Appl Physiol 2007; 103:700-709.
29. Hallstrand TS, Moody MW, Aitken ML, Henderson WR, Jr. Airway immunopathology of asthma with exercise-induced bronchoconstriction. J Allergy Clin Immunol 2005; 116:586-593.
30. Frieri M. Advances in the understanding of allergic asthma. Allergy Asthma Proc 2007; 28: 614-619.
31. Hallstrand TS, Moody MW, Wurfel MM, Schwartz LB, Henderson WR, Jr., Aitken ML. Inflammatory basis of exercise-induced bronchoconstriction. Am J Respir Crit Care Med 2005; 172:679-686.
32. Hallstrand TS, Chi EY, Singer AG, Gelb MH, Henderson WR, Jr. Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness. Am J Respir Crit Care Med 2007; 176:1072-1078.
33. Hilberg T. Etiology of exercise-induced asthma: physical stress-induced transcription. Curr Allergy Asthma Rep 2007; 7:27-32.
34. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, Kundu S, Zhang J, Seidenberg BC, Reiss TF. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339:147-152.
35. Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 2008; 121:383-389.
36. Pearlman DS, v an Adelsberg J , Philip G, T illes SA, Busse W, Hendeles L, Loeys T, Dass SB, Reiss TF. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol 2006; 97:98-104.
37. Philip G, Pearlman DS, Villaran C, Legrand C, Loeys T, Langdon RB, Reiss TF. Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction. Chest 2007; 132:875-883.
38. Bisgaard H, Groth S, Madsen F. Bronchial hyperreactivity to leucotriene D4 and histamine in exogenous asthma. Br Med J (Clin Res Ed) 1985; 290:1468-1471.
39. Fahy JV. Remodeling of the airway epithelium in asthma. Am J Respir Crit Care Med 2001; 164:S46-51.
40. Hallstrand TS, Debley JS, Farin FM, Henderson WR, Jr. Role of MUC5AC in the pathogenesis of exercise-induced bronchoconstriction. J Allergy Clin Immunol 2007; 119:1092-1098.
41. Helenius I, Rytila P, Sarna S, Lumme A, Helenius M, Remes V, Haahtela T. Effect of continuing or finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: a 5-year prospective follow-up study of 42 highly trained swimmers. J Allergy Clin Immunol 2002; 109:962-968.
42. Bernard A, Carbonnelle S, Dumont X, Nickmilder M. Infant swimming practice, pulmonary epithelium integrity, and the risk of allergic and respiratory diseases later in childhood. Pediatrics 2007; 119:1095-1103.
43. Randolph C. Making the diagnosis of asthma in the athlete. Clin Rev Allergy Immunol 2005; 29: 113-123.
44. Wood RP, 2nd, Milgrom H. Vocal cord dysfunction. J Allergy Clin Immunol 1996; 98:481-485.
45. Leggit J. Vocal cord dysfunction. Am Fam Physician 2004; 69:1045-1046.
46. Mannix ET, Manfredi F, Farber MO. A comparison of two challenge tests for identifying exercise-induced bronchospasm in 2 gure skaters. Chest 1999; 115:649-653.
47. Anderson SD, Argyros GJ, Magnussen H, Holzer K. Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction. Br J Sports Med 2001; 35:344-347.
48. Hurwitz KM, Argyros GJ, Roach JM, Eliasson AH, Phillips YY. Interpretation of eucapnic voluntary hyperventilation in the diagnosis of asthma. Chest 1995; 108:1240-1245.
49. Guide for Managing Asthma in Children. American Academy of Allergy, Asthma & Immunology. Available at: http://www.aaaai.org/members/resources/ initiatives/pediatricasthmaguidelines. Last accessed August 30, 2007.
50. Chadwick S. The impact of asthma in an inner city general practice. Child Care Health Dev 1996; 22:175-186.
51. Walsh M, Ryan-Wenger NM. Sources of stress in children with asthma. J Sch Health 1992; 62:459-463.
52. Hallstrand TS, Curtis JR, Aitken ML, Sullivan SD. Quality of life in adolescents with mild asthma. Pediatr Pulmonol 2003; 36:536-543.
53. de Bisschop C, Guenard H, Desnot P, Vergeret J. Reduction of exercise-induced asthma in children by short, repeated warm ups. Br J Sports Med 1999; 33:100-104.
54. Beuther DA, Martin RJ. Efficacy of a heat exchanger mask in cold exercise-induced asthma. Chest 2006; 129:1188-1193.
55. Pearlman D, Milgrom H, Till D, Ziehmer B. Effect of formoterol fumarate treatment on exercise-induced bronchoconstriction in children. Ann Allergy Asthma Immunol 2006; 97:382-388.
56. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Available at: http://www.ginasthma.com. Last accessed April 19, 2007.
57. Hav erkamp HC, D empsey JA, Pegelow DF, M iller JD, Romer LM, Santana M, Eldridge MW. Treatment of airway inflammation improves exercise pulmonary gas exchange and performance in asthmatic subjects. J Allergy Clin Immunol 2007; 120:39-47.
58. Spooner CH, Spooner GR, Rowe BH. Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction. Cochrane Database Syst Rev 2003; CD002307.
59. Hermansen MN, Nielsen KG, Buchvald F, Jespersen JJ, Bengtsson T, Bisgaard H. Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma. Chest 2006; 129:1203-1209.
60. Foradil® Aerolizer® (formoterol fumarate inhalation powder). Full prescribing information. Kenilworth, NJ: Schering Corporation, 2006.
61. Serevent® (salmeterol xinafoate inhalation powder). Full prescribing information. Research Triangle Park, NC: GlaxoSmithKilne, 2006.
62. Bronsky EA, Yegen U, Yeh CM, Larsen LV, Della Cioppa G. Formoterol provides long-lasting protection against exercise-induced bronchospasm. Ann Allergy Asthma Immunol 2002; 89:407-412.
63. Shapiro GS, Yegen U, Xiang J, Kottakis J, Della Cioppa G. A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. Clin Ther 2002; 24:2077-2087.
64. Daugbjerg P, Nielsen KG, Skov M, Bisgaard H. Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children. A cta Paediatr 1996; 85:684-687.
65. Boner AL, Spezia E, Piovesan P, Chiocca E, Maiocchi G. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 1994; 149:935-939.
66. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992; 89:1176-1182.
67. Gronnerod TA, von Berg A, Schwabe G, Soliman S. Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir Med 2000; 94:661-667.
68. Blake K, Pearlman DS, Scott C, Wang Y, Stahl E, Arledge T. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Ann Allergy Asthma Immunol 1999; 82:205-211.
69. Ferrari M, Segattini C, Zanon R, Bertaiola M, Balestreri F, Brotto E, Lo Cascio V. Comparison of the protective effect of formoterol and of salmeterol against exercise-induced bronchospasm when given immediately before a cycloergometric test. Respiration 2002; 69:509-512.
70. Richter K, Janicki S, Jorres RA, Magnussen H. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J 2002; 19:865-871.
71. Bisgaard H. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature. Pediatr Pulmonol 2000; 29:221-234.
72. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997; 99:655-659.
73. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108:1235-1239.
74. Booth H, Bish R, Walters J, Whitehead F, Walters EH. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1996; 51:1100-1104.
75. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Am J Respir Crit Care Med 1996; 154:1603-1607.
76. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88:363-368.
77. Garcia R, Guerra P, Feo F, Galindo PA, Gomez E, Borja J, Fernandez-Pacheco R. Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm. J Investig Allergol Clin Immunol 2001; 11:176-182.
78. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2006; 61:91.
79. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
80. US Food and Drug Administration. FDA Public Health Advisory: Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (Duticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder). Available at: http://www.fda.gov/cder/drug/ advisory/LABA.htm. Last accessed December 4, 2006.
81. Advair Diskus® (Duticasone propionate and salmeterol inhalation powder). Full prescribing information. Research Triangle Park, NC: GlaxoSmithKline, 2006.
82. Symbicort® Inhalation Aerosol (budesonide and formoterol fumarate dihydrate). Full prescribing information. Wilmington, DE: AstraZeneca LP, 2007.
83. Maesen FP, Smeets JJ, Gubbelmans HL, Zweers PG. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours. Chest 1990; 97:590-594.
84. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10:2484-2489.
85. Cardona I, D'Alonzo GE, Jr., Becker J. A pilot survey of beta2-agonist inhaler availability for children with asthma during organized sporting events. Ann Allergy Asthma Immunol 2004; 92: 340-343.